Lexy Kelley, MD

Dedicated Medical Director brings strong leadership and 19 years experience in clinical development and medical affairs roles in Pharma and Medical Device companies. Indication background includes rheumatology, autoimmune, rare disease, dermatology, infectious disease, hematology, and women’s health. Clinical development phases 1 – 4 experience including clinical development documents, regulatory support and overall patient safety responsibilities. MSL training, KOL communications and global advisory board management for pre and post marketed products.

Georgia Medical License, current

• Successful testing protocols in virology, Clinical Chemistry, 2001 Aug, Kelley VA, Caliendo AM
• Determination of the average percent von Willebrand Factor-Cleaving Protease (VWF-CP) activity in donor plasma, Blood, 2001 November, Kelley VA, Hillyer KL, Roush KR, Long E, Barclay SB, Duncan A, Hillyer CD
• Von Willebrand Factor Cleaving Protease (VWF-CP) activity in S-59 treated donor plasma, Blood, 2001 November, Hillyer KL, Kelley VA, Roush KR, Long E, Barclay SB, Duncan A, Hillyer CD
• Lack of seronegative Hepatitis C Virus infections in patients with chronic renal failure, Transplantation, 2002 Nov, Kelley VA, Everett-Kitchens J, Brannon L, Connor K, Martinez EJ, Pearson T, Nolte F
• Cost Effectiveness of Autologous Blood Donations, Abstract AABB 2002, May, Press C, Kelley VA, Phillips V, Stramer S, Hillyer CD
• Survey of Current Surveillance Methods DRSP, MRSA, VISA/VRSA, 2005, 2005 Conference on Antimicrobial Resistance Programs: Building Bridges: Surveillance – Intervention – Evaluation, Atlanta, Georgia, April 26-29, 2005, Noggle B, Kelley VA
• Characterization of a Humanized Monoclonal Antibody Recognizing Clumping Factor A, Antimicrobial Agents and Chemotherapy, 2006 Aug, Weems J, Steinberg J, Filler S, Baddley J, Corey GR, Sampathkumar P, Winston L, Lowy F, John J, Kubin C, Talwani R, Moore T, Patti J, Hetherington S, Texter M, Wenzel E, Kelley V, Fowler
• Data Quality Challenges in Systemic Lupus Erythematosus Trials: How Can This Be Optimized?, Current Rheumatology Reports, Online May 2012, Pike M, Kelley L
• Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from the ALLEVIATE study and extension SL0006, Rheumatology, 2013, online March 29, Wallace DJ, Gordon C, Strand V, Hobbs K, Petri M, Kalunian K, Houssiau F, Tak PP, Kelley L, Kilgallen B, Wegener W, Isenberg D, Barry A, Goldenberg D
• Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus : results from EMBLEM, a phase IIb, randomized, double-blind, placebo-controlled, multicenter study, Annals of the Rheumatic Diseases, Online First, 12 January 2013, Wallace DJ, Kalunian K, Petri M, Strand V, Houssiau F, Pike M, Kilgallen B, Barry A, Kelley L, Bongardt S, Gordon C
• Epratuzumab demonstrates clinically meaningful improvements in patients with moderate-to-severe systemic lupus erythematosus (SLE): results from EMBLEM, 8th European Lupus Meeting (ELM), Porto, Portugal, April 6-9 2011, Gordon C, Petri M, Kalunian K, Strand V, Houssiau F, Pike M, Kilgallen B, Kelley L, Wallace, D.J.
• Epratuzumab demonstrates clinically meaningful improvements in patients with moderate-to-severe systemic lupus erythematosus (SLE): results from EMBLEM, British Society for Rheumatology (BSR), Glasgow, UK, 1-3 May 2012, Gordon C, Petri M, Kalunian K, Strand V, Houssiau F, Pike M, Kilgallen B, Kelley L, Wallace, D.J.
• Systemic Lupus Erythematosus Responder Index assessment of responders in EMBLEM, a phase IIb study in patients with moderate to severe systemic lupus erythematosus, ACR/ARHP Scientific Meeting 2011, Chicago, IL, USA, November 4-5, Petri M, Pike M, Kelley L, Kilgallen B, Gordon C
• Epratuzumab demonstrates clinically meaningful improvements in patients with moderate/severe flaring systemic lupus erythematosus: results from the ALLEVIATE study and extension SL0006, Rheumatology, 2013, online March 29, Wallace DJ, Gordon C, Strand V, Hobbs K, Petri M, Kalunian K, Houssiau F, Tak PP, Kelley L, Kilgallen B, Wegener W, Isenberg D, Barry A, Goldenberg D
• Epratuzumab demonstrates clinically meaningful improvements in patients with moderate/severe flaring systemic lupus erythematosus: results from the ALLEVIATE study and extension SL0006